Janux Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Janux Therapeutics
JANX Stock  USD 46.39  1.61  3.35%   
Janux Therapeutics financial statements provide useful quarterly and yearly information to potential Janux Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Janux Therapeutics financial statements helps investors assess Janux Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Janux Therapeutics' valuation are summarized below:
Gross Profit
-44.8 M
Market Capitalization
2.4 B
Enterprise Value Revenue
137.9447
Revenue
13 M
Earnings Share
(1.17)
We have found one hundred twenty available fundamental trends for Janux Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Janux Therapeutics regular market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 863.6 M in 2024. Enterprise Value is likely to rise to about 850.2 M in 2024

Janux Therapeutics Total Revenue

4.56 Million

Check Janux Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Janux Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 13.1 M, Depreciation And Amortization of 2.1 M or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 55.51, Dividend Yield of 0.0 or PTB Ratio of 1.44. Janux financial statements analysis is a perfect complement when working with Janux Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Janux Therapeutics Correlation against competitors.
For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Janux Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets251.1 M380.4 M93.2 M
Slightly volatile
Short and Long Term Debt Total14.9 M24.5 M7 M
Slightly volatile
Other Current Liabilities4.6 M7.4 M1.9 M
Slightly volatile
Total Current Liabilities11 M13 M6.9 M
Slightly volatile
Property Plant And Equipment Net29.2 M27.8 M5.9 M
Slightly volatile
Accounts Payable1.7 M2.4 M789.4 K
Slightly volatile
Cash25.2 M19.2 M9.7 M
Slightly volatile
Non Current Assets Total32.7 M31.2 M6.6 M
Slightly volatile
Cash And Short Term Investments232 M344 M86.2 M
Slightly volatile
Common Stock Total Equity50.7 K48.3 K12.9 K
Slightly volatile
Common Stock Shares Outstanding46.2 M44 M42 M
Slightly volatile
Liabilities And Stockholders Equity251.1 M380.4 M93.2 M
Slightly volatile
Non Current Liabilities Total18.1 M23 M9.1 M
Slightly volatile
Other Stockholder Equity308.5 M512.4 M114.1 M
Slightly volatile
Total Liabilities29.1 M36.1 M15.9 M
Slightly volatile
Property Plant And Equipment Gross32.3 M30.8 M6.3 M
Slightly volatile
Short and Long Term Debt3.2 M3.6 M3.9 M
Slightly volatile
Total Current Assets236.6 M349.2 M87.9 M
Slightly volatile
Capital Stock28.8 K46 K11.3 K
Slightly volatile
Short Term Debt1.3 M1.5 M3 M
Slightly volatile
Common Stock28.8 K46 K11.3 K
Slightly volatile
Property Plant Equipment8.6 M8.1 M1.7 M
Slightly volatile
Other Liabilities2.4 M2 M4.9 M
Slightly volatile
Current Deferred Revenue2.8 M1.7 M2.4 M
Slightly volatile
Other Current Assets4.2 M5.2 M1.6 M
Slightly volatile
Other Assets1.9 M2.5 M1.4 M
Slightly volatile
Capital Surpluse465.7 M497.6 M424.2 M
Slightly volatile
Non Current Liabilities Other32.3 M30.8 M6.6 M
Slightly volatile

Janux Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.1 M2 M335.6 K
Slightly volatile
Interest Expense4.9 M4.6 M1.1 M
Slightly volatile
Selling General Administrative13.5 M26.1 M5.4 M
Slightly volatile
Other Operating Expenses44.4 M81.1 M18.7 M
Slightly volatile
Research Development30.9 M54.9 M13.2 M
Slightly volatile
Cost Of Revenue1.9 M2 M7.7 M
Slightly volatile
Total Operating Expenses44.4 M81.1 M18.7 M
Slightly volatile
Reconciled Depreciation1.9 M1.8 M318.2 K
Slightly volatile
Non Operating Income Net Other2.4 M4.6 M940.8 K
Slightly volatile

Janux Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings25.6 M26.9 M19.9 M
Slightly volatile
Stock Based Compensation21 M20 M4.4 M
Slightly volatile
Begin Period Cash Flow54.9 M52.2 M10.5 M
Slightly volatile
Other Cashflows From Financing Activities5.7 M6 M16.8 M
Pretty Stable
Depreciation2.1 M2 M335.6 K
Slightly volatile
Capital Expenditures2.8 M1.9 M1.9 M
Slightly volatile
Total Cash From Financing Activities101.7 M59.5 M40 M
Slightly volatile
End Period Cash Flow25.8 M20 M9.9 M
Slightly volatile
Change To Netincome20.8 M19.8 M4.6 M
Slightly volatile
Change To Liabilities3.8 M6.5 M1.6 M
Slightly volatile
Change To Inventory663.3 K955.6 K493.7 K
Slightly volatile
Sale Purchase Of Stock163.3 M183.8 M200.1 M
Slightly volatile
Change Receivables6.4 M7.2 M7.8 M
Slightly volatile
Cash And Cash Equivalents Changes17.8 M14.3 M26.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio55.5158.4306191
Slightly volatile
Stock Based Compensation To Revenue1.72.47491.9314
Pretty Stable
Capex To Depreciation0.90.946311.126
Slightly volatile
EV To Sales56.1459.0909183
Slightly volatile
Payables Turnover0.850.80650.1565
Slightly volatile
Sales General And Administrative To Revenue2.313.23392.8139
Pretty Stable
Research And Ddevelopement To Revenue7.416.79487.1318
Slightly volatile
Capex To Revenue0.220.22890.4058
Very volatile
Cash Per Share4.07.81591.9426
Slightly volatile
Days Payables Outstanding43045312.3 K
Slightly volatile
Income Quality0.80.86760.8715
Slightly volatile
Current Ratio28.1426.79677.4006
Slightly volatile
Graham Number16.0315.26814.4365
Slightly volatile
Capex Per Share0.06220.0420.0461
Slightly volatile
Revenue Per Share0.130.18360.1053
Slightly volatile
Interest Debt Per Share0.590.55760.1921
Slightly volatile
Debt To Assets0.06130.06453.9404
Slightly volatile
Days Of Payables Outstanding43045312.3 K
Slightly volatile
Ebt Per Ebit1.140.79881.0593
Pretty Stable
Long Term Debt To Capitalization0.07360.06270.0707
Pretty Stable
Quick Ratio28.1426.79677.4045
Slightly volatile
Net Income Per E B T1.010.991.0141
Slightly volatile
Cash Ratio1.591.47360.8558
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.21.03661.0956
Slightly volatile
Fixed Asset Turnover0.280.29031.8795
Slightly volatile
Debt Ratio0.06130.06453.9404
Slightly volatile
Price Sales Ratio55.5158.4306191
Slightly volatile
Asset Turnover0.01460.02120.0116
Slightly volatile
Gross Profit Margin0.970.75810.9505
Slightly volatile

Janux Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap863.6 M472.3 M947.2 M
Slightly volatile
Enterprise Value850.2 M477.6 M944.2 M
Slightly volatile

Janux Fundamental Market Drivers

Cash And Short Term Investments344 M

Janux Upcoming Events

8th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Janux Therapeutics Financial Statements

Janux Therapeutics investors use historical fundamental indicators, such as Janux Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Janux Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.7 M2.8 M
Total Revenue8.1 M4.6 M
Cost Of Revenue2 M1.9 M
Stock Based Compensation To Revenue 2.47  1.70 
Sales General And Administrative To Revenue 3.23  2.31 
Research And Ddevelopement To Revenue 6.79  7.41 
Capex To Revenue 0.23  0.22 
Revenue Per Share 0.18  0.13 
Ebit Per Revenue(9.03)(9.48)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY